SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate earnings, with discussions focusing on potential revenue beats and updated guidance. The community is weighing the possibility of a post-earnings surge against concerns of short-term manipulation, and a few investors are citing potential rate cuts as catalysts for the stock.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending amid mixed sentiment, with some traders citing a potential bottom after a period of decline, while others express concerns about manipulation and the company's long-term prospects. A recent NFL apparel partnership is a key catalyst mentioned, though some question its impact, and overall discussion centers on whether the stock is poised for a rebound or further downside. Community members are actively debating analyst ratings and potential activist involvement.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as the company recently launched new AI chips aimed at competing with Nvidia and AMD in the data center market, generating significant buzz and a surge in stock price. Community discussions revolve around the potential impact of these chips, revenue projections, and whether Qualcomm can truly challenge the dominance of existing players. Some analysts express skepticism, citing the chips' specifications and disclosed customer base, while others highlight the company's shift towards AI infrastructure.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending as the company reclaims its original ticker symbol after Overstock's rebranding, sparking discussions of meme stock potential and a possible short squeeze. Community members are debating the impact of blockchain initiatives tied to tZERO and speculating about strategic moves by key figures like Ryan Cohen. Bearish investors cite concerns about dilution and cash burn while bullish investors focus on potential new directions for the company.

Trump For President

Trump Crypto is trending amid mixed community sentiment, with some users discussing potential pumps and scams while others express political opinions related to Trump. Bullish investors are anticipating gains, while bearish investors are pointing to the coin's performance since launch. The coin seems to be moving in response to triggers related to its namesake figure.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as investors weigh the potential impact of a new web browser from OpenAI, a possible competitor to Google Chrome. Despite the concerns, many community members view the dip as a buying opportunity, emphasizing Google's diverse portfolio and strong position in AI and cloud computing.  Additionally, some analysts have recently raised their price targets for the stock, citing positive advertising and cloud channel checks.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to a significant volume spike and discussions around its potential for a parabolic move. Community members are closely watching for continuation and a possible short squeeze, citing a very low float and insider ownership. Some traders are also pointing to a recent revenue growth update as a potential catalyst.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica ($CLS) is trending due to positive community sentiment and strong reactions to recent earnings, with many calling the results a "monster" beat. The community is buzzing about the company's potential, with some drawing comparisons to $NVDA and anticipating significant future growth. The stock's performance is also being discussed in the context of the broader tech sector and AI infrastructure.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending as investors assess the impact of a trial pause due to a patient experiencing liver enzyme elevations, leading to a significant stock drop and analyst price target reductions. The community is debating whether this is an overreaction and a buying opportunity, citing the company's strong cash reserves and continued buy ratings from some analysts. Some traders anticipate a short squeeze, while others express concerns about the long-term implications for NTLA's lead program.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group (UNH) is trending as investors anticipate the company's earnings report, with some expecting a positive surprise due to lowered expectations and potential catalysts like a DOJ decision. The community is actively discussing options strategies, with some bulls hedging their bets, while others express concerns about margin pressures and potential negative impacts. Optimism remains among some, citing Warren Buffett's backing and potential for long-term growth despite near-term challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Aditxt, Inc. (Nasdaq: ADTX) ('Aditxt' or the 'Company'), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ('Pearsanta...

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Equity

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.


Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc...

Shares of Aditxt Inc. (ADTX) slipped in Thursday’s after-hours session after a more than 7% drop during regular trading.&nbsp;Despite the pullback, the penny stock remains up over 45% in the past week as retail interest builds ahead of a key company update.CEO Amro Albanna is set to host a virtual fireside chat on Friday, Feb. 21, at 11:30 AM ET, where he will discuss corporate developments, subsidiary updates, potential transactions, and pipeline advancements.&nbsp;The event will cover&nbsp;subsidiary Adimune, Inc. and its focus on autoimmunity treatments, including Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome.Albanna will also touch upon another subsidiary, Pearsanta Inc., discussing its progress in early cancer detection and its planned IPO in 2025.<stembedurl>https://stocktwits.com/Ztraderguy/message/604934960</stembedurl><stembedurl>https://stocktwits.com/Ronin2024/message/605087805</stembedurl>Aditxt, which has lost over 99% of its value in the past year, has been on an acquisition spree to strengthen its portfolio.&nbsp;In October, the company outlined its year-end plans, including acquisitions of Evofem Biosciences (EVFM) and Appili Therapeutics (APLIF), which generated $7.8 million in revenue for the six months ended June 30, 2024.With a market cap under $10 million, Aditxt said in October that it is working to clean up its balance sheet, reduce its $19 million in accounts payable, and secure funding to complete its planned acquisitions.&nbsp;Albanna previously highlighted the company’s Nasdaq listing, debt reduction, and strategic capital access as critical to its future.Shares of Aditxt are down over 39% year-to-date. Short interest soared from 0.7% at the beginning of 2025 to 9.3% by the end of last week, according to Koyfin data.Retail traders will be closely watching Friday’s event for potential catalysts that could drive further price action.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Microcap Biotech Aditxt Rallies Retail Interest Ahead Of CEO’s Fireside Chat: What’s On Investors’ Radar?

The event will cover Adimune, Inc., which focuses on autoimmunity treatments, and subsidiary Pearsanta's planned IPO in 2025.

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Aditxt, Inc. (Aditxt or the Company) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced that it will host a virtual Fireside Chat on...

Aditxts Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has...

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. (Adimune...

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 PR Newswire SAN DIEGO, Nov. 14, 2024 Improved...

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the...

Aditxts Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Mountain View, CA.

Aditxt Inc

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

ADTX
Aditxt Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ADTX News

ADTXAditxt Inc